Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging through Artivion’s FDA updates, clinical-trial costs, and global device revenues can feel overwhelming when each SEC report stretches well past 200 pages. Whether you are tracking new aortic stent graft approvals or trying to spot shifts in mechanical heart-valve demand, the technical language in an Artivion annual report 10-K or a fresh 10-Q quarterly earnings report often masks the insights that drive decisions.
Stock Titan solves this problem. Our AI engine turns every filing into plain-English takeaways—Artivion SEC filings explained simply. Get instant alerts the moment an Artivion 8-K material event lands on EDGAR, skim AI-generated risk highlights, or drill straight into segment revenue tables without sifting through footnotes. Need to monitor management’s sentiment? Real-time dashboards surface Artivion Form 4 insider transactions so you can gauge executive conviction ahead of pivotal FDA milestones.
The platform covers every document type investors ask about:
- 10-K sections on product liability and clinical data—already summarized and compared year-over-year.
- 10-Q snapshots for revenue growth by valve, graft, and adhesive lines—ideal for quick Artivion earnings report filing analysis.
- 8-K event briefs that explain recall notices or trial results in minutes.
- Proxy statements outlining Artivion executive compensation and option grants.
- Form 4 dashboards showing Artivion insider trading Form 4 transactions in real time.
Artivion, Inc. (AORT) insider transaction: the VP, Chief Accounting Officer reported a sale of 1,789 shares of common stock on 11/10/2025 at $44.619 per share. Following the transaction, the reporting person beneficially owns 144,862 shares, held directly.
The filing states the shares were sold to cover taxes due upon the vesting of restricted stock units, described as a “sell to cover” and not a discretionary trade.
Artivion, Inc. (AORT) disclosed an insider transaction by its SVP, Clinical & MD Affairs. On 11/10/2025, the officer sold 2,566 shares of common stock at $44.619 per share. The filing states the shares were sold upon the vesting of restricted stock units to cover tax withholding, described as a “sell to cover” and not a discretionary trade.
Following the transaction, the officer directly beneficially owned 61,634 shares. The report was filed as a single‑person Form 4 submission.
AORT received a Rule 144 notice for a proposed sale of 2,566 common shares through Fidelity Brokerage Services, with an aggregate market value of $114,492.10. The approximate sale date is 11/11/2025 on the NYSE.
The shares were acquired on 11/07/2025 via restricted stock vesting from the issuer as compensation. A separate table shows a sale of 18,200 shares on 08/27/2025 by Marshall S. Stanton, for $801,211.32 in gross proceeds. Shares outstanding were 47,374,939.
AORT: An affiliate filed a Form 144 notice to sell up to 17,580 shares of common stock, reflecting an aggregate market value of $784,400.26. The filing lists an approximate sale date of 11/10/2025 on the NYSE through Fidelity Brokerage Services LLC.
The shares were acquired on 11/07/2025 via restricted stock vesting from the issuer as compensation. The filer also reported sales in the past three months: 12,500 shares on 08/15/2025 for gross proceeds of $528,991.00. Shares outstanding were 47,374,939; this is a baseline figure, not the amount being sold.
Artivion (AORT) received a Form 144 notice from a shareholder for a proposed sale of 10,000 common shares with an aggregate market value of $461,800. The filing lists an approximate sale date of 11/11/2025 on the NYSE through Fidelity Brokerage Services LLC.
The securities to be sold were acquired from the issuer via an option granted on 11/08/2022, with acquisition and cash payment dated 11/11/2025. Shares outstanding were 47,374,939.
The filer reported prior sales in the last three months: 23,356 shares on 08/12/2025 for $1,004,605.97 and 10,000 shares on 08/25/2025 for $443,700.00.
Form 144 notice of proposed sale: A shareholder filed to sell up to 2,960 shares of common stock through Fidelity Brokerage Services, with an aggregate market value of $132,071.94. The filing lists an approximate sale date of 11/11/2025 on the NYSE.
The shares were acquired on 11/07/2025 via restricted stock vesting from the issuer, in an amount of 2,960 shares, treated as compensation. Shares outstanding were 47,374,939 at the time referenced in the form; this is a baseline figure, not the amount being sold.
The person for whose account the securities are to be sold reported prior sales in the past three months: 23,356 shares on 08/12/2025 for gross proceeds of $1,004,605.97, and 10,000 shares on 08/25/2025 for gross proceeds of $443,700.00.
Artivion (AORT) received a Form 144 notice indicating a planned sale of up to 1,789 shares of common stock. The filing lists an aggregate market value of $79,823.21 and an approximate sale date of 11/10/2025 on the NYSE through Fidelity Brokerage Services LLC.
The seller acquired these shares on 11/07/2025 via restricted stock vesting from the issuer as compensation. Shares outstanding were 47,374,939, providing scale relative to the proposed sale.
Artivion (AORT): Notice of proposed sale under Rule 144. A filing indicates an intent to sell 3,373 common shares, with an approximate sale date of 11/10/2025. The filing lists an aggregate market value of $150,499.55, with trading on the NYSE.
The shares were acquired on 11/07/2025 via restricted stock vesting from the issuer, recorded as compensation. As context, 47,374,939 shares were outstanding. In the past three months, the named seller reported a sale of 10,802 shares on 08/12/2025 for $471,752.51.
This is an administrative notice of a potential sale under Rule 144 and does not itself execute a transaction.
Morgan Stanley filed Schedule 13G/A (Amendment No. 2) reporting beneficial ownership of 2,074,975 shares of Artivion, Inc. (AORT) common stock, representing 4.4% of the class as of the reporting event dated 09/30/2025. The filing states Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class.
The filing lists shared voting power: 208,344 shares and shared dispositive power: 2,074,975 shares, with 0 shares under sole voting or dispositive power. The certification indicates the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Artivion (AORT) reported third‑quarter 2025 results with total revenues of $113.4 million, up 18% year over year. Medical devices drove growth, led by aortic stent grafts $39.6 million (+38%) and On‑X $26.8 million (+25%), while preservation services contributed $25.7 million (+5%). Gross margin was $74.4 million, and operating income rose to $12.5 million.
Net income was $6.5 million (diluted EPS $0.13) versus a loss a year ago, aided by a $3.5 million PerClot sales milestone gain. Operating cash flow reached $20.3 million year to date, ending cash was $73.4 million. The company eliminated its $100.0 million Convertible Senior Notes via exchanges into ~4.35 million shares and small residual settlement, reducing interest expense. A credit amendment extended maturities to January 18, 2031 and lowered interest margins; total principal debt stood at $220.0 million with long‑term debt (net) of $214.9 million. Shares outstanding were 47,374,939 as of October 31, 2025.
FAQ
What is the current stock price of Artivion (AORT)?
What is the market cap of Artivion (AORT)?
